Some drugs can make the prevention of atherosclerosis through physical exercises more efficient

Abstract

The hypothesis is proposed that fibrates, SGLT2 inhibitors and PDE5 inhibitors can have the same effect as metabolic medication (l-arginine and antioxidants) to amplify the action of physical exercises in inhibiting the formation of atheroma plaques. Moreover, the respective drugs could shorten the duration of a training session. The hypothesis can be tested on rats, but the association of some of the listed drugs with physical exercises presents some risks: clofibrate can cause muscular syndrome, dapagliflozin prevents the improvement of insulin sensitivity in obese patients, and sidenafil can affect renal function in patients with heart failure. The good part is that SGLT2 inhibitors increase the exercise capacity of patients with heart failure, dapagliflozin can prevent diabetic cardiomyopathy in patients with type 2 diabetes mellitus, and PDE5 inhibitors can be combined with physical exercises in patients with stable coronary artery disease, heart failure or pulmonary hypertension. All these conditions are associated with atherosclerosis, which is a reason for the implementation of these therapeutic methods.